Prostate cancer is one of the most common cancer worldwide. Androgen deprivation therapy (ADT) is the standard of front-line treatment for metastatic prostate cancer. Most of the patients develop metastatic castration-resistant prostate cancer (mCRPC) after receiving ADT. Although the androgen metabolism inhibitor, e.g. abiraterone, or the second-generation ADT, e.g. enzalutamide, are used as the second-line treatment for mCPRC, the disease ultimately develops resistance. In the previous study, PARP inhibitors had shown clinical benefits in mCRPC patients with homologous recombination repair (HRR) gene mutations. In the European Society for Medical Oncology (ESMO) Congress 2019, the results of a phase III study (PROfound) were presented. Olaparib significantly improved median radiographic progression-free survival (5.82m vs 3.52m, HR=0.49, 95% CI=0.38-0.63), objective response rate (21.7% vs 4.5%, OR=5.93, 95% CI=2.01-25.40), and overall survival (17.51m vs 14.26m, HR=0.67, 95% CI=0.49-0.93) in mCRPC patients with HRR gene mutations versus treatment of physician’s choice. These data indicated HRR gene mutations were associated with clinical benefits in heavily pretreated mCRPC patients who received olaparib treatment.
Source : Hussain M, et al. ESMO Congress 2019